在第三阶段肺状细胞癌中,术后化疗的生存益处基于SEER数据库分析,通过倾向性得分匹配
1Department of Cardiothoracic Surgery, Jinhua Municipal Central Hospital, No. 365 Renmin East Road, Jinhua, 321000, Zhejiang Province, China.
Scientific reports
|July 2, 2025
概括
手术后的化疗显著改善了大多数第三阶段肺状细胞癌 (LUSC) 患者的生存率. 这种益处在晚期结节疾病和主要肺切除中最为明显,有助于临床决策.
科学领域:
- 在瘤学瘤学.
- 胸部外科手术 胸部外科手术
- 临床药理学 临床药理学
背景情况:
- 肺状细胞癌 (LUSC) 是肺癌的主要亚型.
- 第三阶段LUSC带来了重大的治疗挑战.
- 在III期LUSC中术后化疗的作用需要进一步澄清.
研究的目的:
- 评估术后化疗对III期LUSC患者整体存活时间 (OS) 的影响.
- 分析跨患者子组的生存异质性.
- 在这个人群中确定OS的预后因素.
主要方法:
- 使用SEER数据库 (2010-2015) 的回顾性队列研究.
- 倾向性得分匹配 (PSM) 来控制混因子.
- 卡普兰-梅尔曲线和考克斯回归用于生存和预后因子分析.
主要成果:
- 术后化疗与显著的生存益处有关 (调整HR:0.62,P<0.001).
- 绝对5年后的生存率在化疗后从28%提高到42%.
- 化疗改善了大多数子组的生存率,特别是N1-2疾病和重大切除.
结论:
- 术后化疗为III期LUSC患者提供了显著的生存优势.
- 治疗决策可以通过子组分析得出结论,特别是在晚期结节参与或广泛肺切除的患者中.
- 进一步研究优化化疗在LUSC的应用是有必要的.
更多相关视频
06:46Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
Published on: September 27, 2024
381
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
10.6K
相关概念视频
Cancer Survival Analysis
458
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
458
Comparing the Survival Analysis of Two or More Groups
299
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
299
Kaplan-Meier Approach
277
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
277
